Yesterday
Forced smiles: Crescent Capital, Genesis get their fangs out
Pacific Smiles has been in a holding pattern since the dispute broke out.
- Sarah Thompson, Kanika Sood and Emma Rapaport
This Month
Growth PE firm Whiteoak adds NDIS software provider
Whiteoak, a private equity firm founded by ex McKinsey & Co consultant Richard Whiteoak, has picked up a majority stake in Datanova.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Deutsche Bank backs $210m Bendigo Hospital public-private refinance
Street Talk understands the German bank has come in as the project’s long-term lender, refinancing an existing bank syndicate.
- Sarah Thompson, Kanika Sood and Emma Rapaport
I-MED snaps up US teleradiology player StatRad
Aussie imaging giant I-MED is hoping to recreate its fast-growing teleradiology business in the US with a major acquisition.
- Tess Bennett
$200m-a-year Opal HealthCare courts buyers; Morgan Stanley hired
While it remains to be seen how much of the business will be on offer, a big enough cheque will no doubt get everyone on board.
- Sarah Thompson, Kanika Sood and Emma Rapaport
June
AI beats the experts at detecting prostate cancer
When international AI teams competed with a pool of 62 radiologists in the first large-scale contest to diagnose prostate cancer, the machine won.
- Jill Margo
The Ozempic effect: How weight loss wonder drug gobbled up an economy
Pharmaceutical giant Novo Nordisk has grown so large in its native Denmark that it’s hard to find staff. Meanwhile, its philanthropic foundation is running out of local causes to support.
- Sanne Wass and Naomi Kresge
Radiopharm in $65m raise; Nasdaq-listed strategic pays 47pc premium
Diagnostics specialist Lantheus, capitalised at $8 billion on the Nasdaq, likes the look of Aussie company Radiopharm Theranostics.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Radiology’s AI future and deregulation help end years of bad blood
The No.1 player in an industry sets the tone. And in radiology, the tone is deals, deals, deals.
- Anthony Macdonald
Integral Diagnostics dealmaking creates $1b diagnostics giant
The company has proposed a merger with its smaller rival, Capitol Health, creating the largest pure-play diagnostics imaging group on the ASX.
- Kylar Loussikian
Aussie high-flyer’s wings clipped by US investors
Red-hot biotech Telix got a shock when US investors wanted a chunky discount to buy stock. So it’s walking away looking silly, but with its pride intact.
- Anthony Macdonald
Telix pulls $300m Nasdaq IPO as investors demand deep discount
The cancer treatment hopeful had announced plans to list in New York only last week as it searched for more capital. On Friday, it withdrew from the initial public offering.
- Kylar Loussikian
Eight tips to lose weight fast - and safely
Is the crash diet back? Science now suggests that rapidly losing a lot of weight could be a beneficial strategy for health – if you do it carefully.
- Juliette Kellow
- Exclusive
- Mergers & acquisitions
Competition concerns stalk Chemist Warehouse’s $8.8b Sigma deal
A Singaporean hedge fund warns the “smart money was playing dumb” on a deal that means the merged group will be the only major player in Darwin and control 68 per cent of Melbourne’s market.
- Jemima Whyte and Jonathan Shapiro
Hanwha tussles with Austal board over ‘unfair’ diligence conditions
Austal’s would-be acquirer reckons that its third indicative bid was at least 15 per cent higher than that of Cerberus Capital Management.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Telix greenlights $300m Nasdaq listing in search for deep pockets
It is the second ASX-listed growth stock to flag intentions to list in New York, with Life360, the developer of family social media apps, to debut overnight.
- Joshua Peach
How to dementia-proof your life in your 40s
Research shows that this decade plays a crucial role in predicting your future brain health – and nobody knows why.
- Charlotte Lytton
- Exclusive
- Funding
Aussie vaccine start-up scores $300m valuation
GPN Vaccines has raised $18 million in a round led by Forepont Capital and Kern Capital.
- Yolanda Redrup
Vitamins group Homart brings in Ords, CLSA as it preps for ASX float
As it heads toward the bourse it is bulking up, acquiring New Zealand group Thompson’s Herbals and Thursday Plantation, a natural essential oils business.
- Simon Evans
- Exclusive
- Healthcare
GenesisCare’s valuation shrinks to less than $500m after bankruptcy
Once a global cancer services giant, the company’s new owners are buying back shares from local backers for just $0.000186 as the business is restructured.
- Carrie LaFrenz